2. Signaling Pathways
  3. Immunology/Inflammation
  4. Mucin
  5. Mucin Inhibitor

Mucin Inhibitor

Mucin Inhibitors (5):

Cat. No. Product Name Effect Purity
  • HY-P99362
    Ensituximab
    		Inhibitor
    Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer.
  • HY-P99591
    Sontuzumab
    		Inhibitor 99.66%
    Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer.
  • HY-P99968
    Clivatuzumab
    		Inhibitor ≥99.0%
    Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers.
  • HY-160109A
    Ac5GalNTGc epimer
    		Inhibitor 98.39%
    Ac5GalNTGc epimer is an analogue of hexosamine and the racemate of Ac5GalNTGc (HY-160109). Ac5GalNTGc inhibits mucin-type O-linked glycosylation biosynthesis.
  • HY-158333
    Tasuldine
    		Inhibitor
    Tasuldine is a mucolytic agent, which decreases the sialomucin content of mucus, improves mucociliary and cough clearance.